Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PDS
4426
Precision Drilling
PDS
$1.07B
| $130K | ﹤0.01% |
1,813
+1,803
| +18,030% | +$111K |
|
4427
Advantage Solutions
ADV
$387M
| $129K | ﹤0.01% |
5,873
+563
| +11% | +$16.3K |
|
|
PONY
4428
Pony AI Inc
PONY
$3.68B
| $128K | ﹤0.01% |
8,809
-269,905
| -97% | -$4.49M |
|
4429
AudioEye
AEYE
$73.8M
| $128K | ﹤0.01% |
12,785
+1,015
| +9% | +$13.1K |
|
|
AISP
4430
Airship AI Holdings
AISP
$69.6M
| $128K | ﹤0.01% |
44,188
+16,024
| +57% | +$66K |
|
4431
Cartesian Therapeutics
RNAC
$260M
| $127K | ﹤0.01% |
17,651
-191
| -1% | -$1.54K |
|
|
AIRO
4432
AIRO Group Holdings
AIRO
$265M
| $127K | ﹤0.01% |
15,520
+5,652
| +57% | +$72.9K |
|
4433
AllianzIM U.S. Equity Buffer10 Aug ETF
AUGT
$32.3M
| $127K | ﹤0.01% |
3,558
-693
| -16% | -$24.4K |
|
4434
Pro-Dex
PDEX
$213M
| $126K | ﹤0.01% |
3,283
+175
| +6% | +$6.05K |
|
4435
Invesco DB Base Metals Fund
DBB
$319M
| $126K | ﹤0.01% |
+5,505
| New | +$120K |
|
4436
Cemex
CX
$16.1B
| $126K | ﹤0.01% |
10,961
+6,017
| +122% | +$62.2K |
|
4437
FT Vest US Equity Enhance & Moderate Buffer ETF December
XDEC
$204M
| $125K | ﹤0.01% |
3,065
-1,943
| -39% | -$78.6K |
|
4438
PUT
Charter Communications
CHTR
$18.8B
| $125K | ﹤0.01% |
600
-39,000
| -98% | -$8.77M |
|
4439
Future Fuel
FF
$279M
| $125K | ﹤0.01% |
39,231
+3,815
| +11% | +$13.7K |
|
4440
NET Power
NPWR
$143M
| $125K | ﹤0.01% |
54,750
+6,970
| +15% | +$21.8K |
|
4441
Waldencast
WALD
$168M
| $125K | ﹤0.01% |
66,337
+6,587
| +11% | +$13.4K |
|
4442
AllianzIM U.S. Equity 6 Month Buffer10 Feb/Aug ETF
SIXF
$48.2M
| $124K | ﹤0.01% |
3,895
-575
| -13% | -$18.1K |
|
4443
CALL
Keros Therapeutics
KROS
$211M
| $124K | ﹤0.01% |
+6,100
| New | +$107K |
|
4444
DocGo
DCGO
$57.4M
| $123K | ﹤0.01% |
139,891
+11,724
| +9% | +$12.5K |
|
|
AVBH
4445
Avidbank Holdings
AVBH
$359M
| $123K | ﹤0.01% |
+4,623
| New | +$120K |
|
4446
POSCO
PKX
$17.3B
| $122K | ﹤0.01% |
2,302
+1,201
| +109% | +$63.3K |
|
|
MPX
4447
DELISTED
Marine Products Corp
MPX
| $121K | ﹤0.01% |
13,819
+1,316
| +11% | +$11.4K |
|
4448
CareCloud
CCLD
$104M
| $121K | ﹤0.01% |
+41,412
| New | +$131K |
|
4449
Duluth Holdings
DLTH
$152M
| $121K | ﹤0.01% |
58,043
+14,136
| +32% | +$41.8K |
|
4450
Corbus Pharmaceuticals
CRBP
$184M
| $120K | ﹤0.01% |
14,758
+10,874
| +280% | +$134K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.